-
公开(公告)号：US10087256B2
公开(公告)日：2018-10-02
申请号：US15401856
申请日：2017-01-09
Applicant: BAYLOR RESEARCH INSTITUTE
Inventor： Jacques F. Banchereau , Gerard Zurawski , Sandra Zurawski , SangKon Oh
IPC: C07K16/28 , C07K14/005 , A61K39/00
Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
-
公开(公告)号：US09315580B2
公开(公告)日：2016-04-19
申请号：US13863131
申请日：2013-04-15
Applicant: Baylor Research Institute
Inventor： Jacques F. Banchereau , Gerard Zurawski , Sandra Zurawski , Eynav Klechevsky , SangKon Oh
IPC: C07K16/00 , C12P21/08 , C07K16/28 , A61K39/00 , A61K39/145 , A61K39/21 , C07K14/47 , C12N7/00 , C07K14/005 , A61K39/12
CPC classification number: C07K16/2896 , A61K39/0011 , A61K39/12 , A61K39/145 , A61K39/21 , A61K2039/505 , A61K2039/5154 , A61K2039/55561 , A61K2039/6056 , C07K14/005 , C07K14/4748 , C07K16/2851 , C07K2319/00 , C07K2319/33 , C12N7/00 , C12N2740/16034 , C12N2760/16134
Abstract: The present invention includes isolated anti-Langerin vaccines, methods for making and using an isolated anti-Langerin antibody or binding fragment thereof and one or more antigenic peptides at the carboxy-terminus of the isolated anti-Langerin antibody, wherein when two or more antigenic peptides are present, the peptides are separated by the one or more linker peptides that comprise at least one glycosylation site. The present invention also includes isolated vectors for the expression of the anti-Langerin antigen delivery vectors and their manufactures and use.
Abstract translation: 本发明包括分离的抗兰格林疫苗，分离的抗 - 兰格林抗体的羧基末端制备和使用分离的抗 - 兰格林抗体或其结合片段和一种或多种抗原肽的方法，其中当两种或多种抗原 存在肽，肽被包含至少一个糖基化位点的一个或多个接头肽隔开。 本发明还包括用于表达抗Langerin抗原递送载体的分离载体及其制备和用途。
-
公开(公告)号：US09234040B2
公开(公告)日：2016-01-12
申请号：US14045454
申请日：2013-10-03
Applicant: Baylor Research Institute
Inventor： Gerard Zurawski , Jacques F. Banchereau , Eynav Klechevsky , Sandra Zurawski , Anne-Laure Flamar
IPC: A61K39/21 , A61K39/145 , A61K39/04 , A61K39/39 , A61K39/395 , C07K16/28 , A61K39/02 , A61K39/12 , A61K47/48 , B82Y5/00 , C12N5/0784 , A61K39/00
CPC classification number: C07K16/2851 , A61K39/02 , A61K39/12 , A61K39/145 , A61K39/21 , A61K47/6897 , A61K47/6901 , A61K2039/505 , A61K2039/6056 , B82Y5/00 , C12N5/0639 , C12N2760/16134
Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
-
Patent Agency Ranking
34.发明申请METHODS AND COMPOSITIONS FOR TREATING BREAST CANCER WITH DENDRITIC CELL VACCINES 有权用于治疗乳腺癌与淋巴细胞疫苗的方法和组合物公开(公告)号：US20150368612A1
公开(公告)日：2015-12-24
申请号：US14719968
申请日：2015-05-22
Applicant: Baylor Research Institute
Inventor： Anna Karolina Palucka , Jacques F. Banchereau , Lee Roberts
IPC: C12N5/0784 , A61N5/10 , A61K38/17 , A61K39/00 , A61K45/06
CPC classification number: C12N5/0639 , A61K31/337 , A61K31/675 , A61K31/704 , A61K35/15 , A61K38/2006 , A61K39/0011 , A61K45/06 , A61K2039/5154 , A61K2039/5158 , A61K2039/545 , A61K2039/6006 , C12N2501/22 , C12N2501/2304 , A61K2300/00
Abstract: Disclosed are compositions and methods for treatment of breast cancer. Disclosed methods and compositions include dendritic cells loaded with cyclin B1 and WT-1 peptide antigens for immunotherapy. These dendritic cell vaccines are administered alone or in combination with other cancer therapies to improve outcomes. Disclosed methods also involve the use of therapeutic agents, such as anakinra, that block the IL-1 inflammation pathway. These agents are used in combination with chemotherapy and/or immunotherapy in treating breast cancer.
Abstract translation: 公开了用于治疗乳腺癌的组合物和方法。 公开的方法和组合物包括负载有用于免疫治疗的细胞周期蛋白B1和WT-1肽抗原的树突状细胞。 这些树突细胞疫苗单独施用或与其他癌症疗法组合施用以改善结果。 所公开的方法还涉及使用阻断IL-1炎症途径的治疗剂，例如阿那白拉。 这些药剂与化疗和/或免疫治疗联合用于治疗乳腺癌。
-
35.发明授权Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells 有权基于在抗原呈递细胞上表达的针对DCIR的靶向抗原的疫苗公开(公告)号：US09102730B2
公开(公告)日：2015-08-11
申请号：US13872793
申请日：2013-04-29
Applicant: Baylor Research Institute
Inventor： Gerard Zurawski , Jacques F. Banchereau , Eynav Klechevsky , Sandra Zurawski , Anne-Laure Flamar
IPC: A61K39/12 , A61K39/145 , A61K39/21 , A61K39/395 , C07K16/46 , C07K16/28 , B82Y5/00 , A61K47/48 , C12N5/0784 , A61K39/02 , A61K39/00
CPC classification number: C07K16/2851 , A61K39/02 , A61K39/12 , A61K39/145 , A61K39/21 , A61K47/6897 , A61K47/6901 , A61K2039/505 , A61K2039/6056 , B82Y5/00 , C12N5/0639 , C12N2760/16134
Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
Abstract translation: 本发明包括使用形成抗体 - 抗原复合物的抗原附着的DCIR特异性抗体或其片段增加抗原呈递的有效性的组合物和方法，其中所述抗原由具有抗体 - 抗原复合物的树突状细胞加工和呈递， 与抗体 - 抗原复合物接触。
-
36.发明申请THERAPEUTIC APPLICATIONS OF ACTIVATION OF HUMAN ANTIGEN-PRESENTING CELLS THROUGH DECTIN-1 审中-公开通过DECTIN-1激活人抗原呈递细胞的治疗应用公开(公告)号：US20140322214A1
公开(公告)日：2014-10-30
申请号：US14264967
申请日：2014-04-29
Applicant: Baylor Research Institute
Inventor： Jacques F. Banchereau , SangKon Oh , Gerard Zurawski , Sandra Zurawski , Ling Ni
CPC classification number: C07K16/2851 , A61K39/395 , A61K2039/5154 , A61K2039/5158 , C07K16/1018 , C07K2317/24 , C07K2317/74 , C07K2317/92 , C07K2319/00 , C12N5/0639 , C12N9/2402 , C12N2501/22 , C12N2501/23 , C12N2501/50 , C12N2501/998
Abstract: The present invention includes compositions and methods for binding Dectin-1 on immune cells with anti-Dectin-1-specific antibodies or fragment thereof capable of activating the immune cells.
Abstract translation: 本发明包括用能够激活免疫细胞的抗Dectin-1特异性抗体或其片段将Dectin-1与免疫细胞结合的组合物和方法。
-
公开(公告)号：US20140030264A1
公开(公告)日：2014-01-30
申请号：US13863131
申请日：2013-04-15
Applicant: Baylor Research Institute
Inventor： Jacques F. Banchereau , Gerard Zurawski , Sandra Zurawski , Eynav Klechevsky , SangKon Oh
IPC: C07K16/28 , C07K14/005 , C07K14/47
CPC classification number: C07K16/2896 , A61K39/0011 , A61K39/12 , A61K39/145 , A61K39/21 , A61K2039/505 , A61K2039/5154 , A61K2039/55561 , A61K2039/6056 , C07K14/005 , C07K14/4748 , C07K16/2851 , C07K2319/00 , C07K2319/33 , C12N7/00 , C12N2740/16034 , C12N2760/16134
Abstract: The present invention includes isolated anti-Langerin vaccines, methods for making and using an isolated anti-Langerin antibody or binding fragment thereof and one or more antigenic peptides at the carboxy-terminus of the isolated anti-Langerin antibody, wherein when two or more antigenic peptides are present, the peptides are separated by the one or more linker peptides that comprise at least one glycosylation site. The present invention also includes isolated vectors for the expression of the anti-Langerin antigen delivery vectors and their manufactures and use.
Abstract translation: 本发明包括分离的抗兰格林疫苗，分离的抗 - 兰格林抗体的羧基末端制备和使用分离的抗 - 兰格林抗体或其结合片段和一种或多种抗原肽的方法，其中当两种或多种抗原 存在肽，肽被包含至少一个糖基化位点的一个或多个接头肽隔开。 本发明还包括用于表达抗Langerin抗原递送载体的分离载体及其制备和用途。
-
38.发明申请VACCINES BASED ON TARGETING ANTIGEN TO DCIR EXPRESSED ON ANTIGEN-PRESENTING CELLS 有权基于抗原向抗原呈递细胞表达的DCIR的抗生素疫苗公开(公告)号：US20130295120A1
公开(公告)日：2013-11-07
申请号：US13872793
申请日：2013-04-29
Applicant: Baylor Research Institute
Inventor： Gerard Zurawski , Jacques F. Banchereau , Eynav Klechevsky , Sandra Zurawski , Anne-Laure Flamar
IPC: C07K16/28 , C12N5/0784
CPC classification number: C07K16/2851 , A61K39/02 , A61K39/12 , A61K39/145 , A61K39/21 , A61K47/6897 , A61K47/6901 , A61K2039/505 , A61K2039/6056 , B82Y5/00 , C12N5/0639 , C12N2760/16134
Abstract: The present invention includes compositions and methods for increasing the effectiveness of antigen presentation using a DCIR-specific antibody or fragment thereof to which an antigen is attached that forms an antibody-antigen complex, wherein the antigen is processed and presented by a dendritic cell that has been contacted with the antibody-antigen complex.
Abstract translation: 本发明包括使用形成抗体 - 抗原复合物的抗原附着的DCIR特异性抗体或其片段增加抗原呈递的有效性的组合物和方法，其中所述抗原由具有抗体 - 抗原复合物的树突状细胞加工和呈递， 与抗体 - 抗原复合物接触。
-
-
-
-
-
-
-
Search Results
38
records
(took 0.037 seconds)
